41789-95-1

Usage

Uses

Used in Pharmaceutical Industry:
3-METHOXY-N-METHYLBENZYLAMINE 97 is used as an intermediate in the synthesis of diclofensine hydrochloride for its role in the development of pain-relieving and anti-inflammatory medications. Its chemical properties contribute to the effectiveness and potency of the final product, making it a crucial component in the pharmaceutical industry.

InChI:InChI=1/C9H13NO/c1-10-7-8-4-3-5-9(6-8)11-2/h3-6,10H,7H2,1-2H3/p+1

Upstream product

• 591-31-1 3-methoxy-benzaldehyde 
• 74-89-5 methylamine 
• 16928-30-6 N-(3-methoxybenzylidene)methanamine 
• 959922-04-4 N-(3-methoxyphenylmethyl)carbamic acid ethyl ester 
• 17101-98-3 (4-methyl-benzyl)carbamic acid ethyl ester 
• 1711-05-3 m-anisoyl chloride 
• 874-98-6 1-bromomethyl-3-methoxybenzene 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 148235-03-4 (3-methoxy-benzyl)-(4-methoxy-benzyl)-methyl-amine 
• 95558-28-4 2-[(3-Methoxy-benzyl)-methyl-amino]-6,6-dimethyl-4-oxo-cyclohex-2-enecarbonitrile 
• 128942-57-4 2-[(3-Methoxy-benzyl)-methyl-amino]-1-phenyl-ethanone 
• 143426-11-3 N-(3-methoxybenzyl)-N-methyl-2,2-diethoxyethylamine 
• 164934-39-8 3-{3-[(3-methoxy-benzyl)-methyl-amino]-propoxy}-xanthen-9-one 
• 164934-40-1 3-{4-[(3-methoxy-benzyl)-methyl-amino]-butoxy}-xanthen-9-one 
• 164934-42-3 4-{2-[(3-methoxy-benzyl)-methyl-amino]-ethoxy}-xanthen-9-one 
• 164934-41-2 2-{2-[(3-methoxy-benzyl)-methyl-amino]-ethoxy}-xanthen-9-one 
• 164934-38-7 3-{2-[(3-methoxy-benzyl)-methyl-amino]-ethoxy}-xanthen-9-one 
• 892405-69-5 2-[(3-methoxy-benzyl)-methyl-amino]-1-thiophen-3-yl-ethanone 
• 41789-94-0 N-(m-Methoxybenzyl)-N-methyl-β-alaninethylester 
• 957113-01-8 C₃₅H₄₆FN₃O₇ 
• 1208333-37-2 C₁₂H₁₉NO₂ 
• 1219730-93-4 C₂₀H₂₆BrN₃O₃ 

Relevant academic research and scientific papers

Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression

Herein, we describe the enabling synthesis of (+)-BMS-820836, a 4,7-disubstituted tetrahydroisoquinoline which was developed as a treatment for a range of neurological diseases, including depression and neurophatic pain. In order to advance the drug candi

Tandem C(sp3)?H Arylation/Oxidation and Arylation/Allylic Substitution of Isoindolinones

Isoindolinones comprise an important class of medicinally active compounds. Herein we report a straightforward functionalization of isoindolinones with aryl bromides (22 examples) using a palladium(II) acetate/NIXANTPHOS-based catalyst system. Additionally 3-aryl-3-hydroxyisoindolinone derivatives, which exhibit anti-tumor activity, can be accessed via a tandem reaction. Thus, when the arylation product is exposed to air under basic conditions, in situ oxidation takes place to install the 3-hydroxy group. Furthermore, a tandem arylation/allylic substitution reaction is advanced in which both the arylation and allylic substitution are catalyzed by the same palladium catalyst. Finally, a tandem arylation/alkylation procedure is presented. These tandem reactions enable the synthesis of a variety of structurally diverse isoindolinone derivatives from common starting materials. (Figure presented.).

CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE

The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Smooth isoindolinone formation from isopropyl carbamates via bischler-napieralski-type cyclization

Isopropyl carbamates derived from benzylamines provide isoindolinones by treatment with phosphorus pentoxide at room temperature. Utility of this Bischler-Napieralski-type cyclization and a new mechanism involving a carbamoyl cation for rationalization of this smooth conversion are discussed.

Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors

RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (～7 mmHg).(22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.

4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41.

Highly enantioselective synthesis of tetrahydroquinolines via cobalt(II)-catalyzed tandem 1,5-hydride transfer/cyclization

A chiral catalyst prepared from N,N′-dioxide and Co(BF 4)2·6H2O was applied in the asymmetric hydride transfer initiated cyclization reaction, giving optically active tetrahydroquinolines in good yields with high enantioselectivities under mild reaction conditions. Meanwhile, in light of the absolute configuration of the product, a possible working model was proposed to explain the origin of the activation and asymmetric induction.

ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF

Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF

Novel [l,2,4]triazolo[l,5-α]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SAl and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-I and N-2 are also described in the present invention.

CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF

Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.